News

The FDA has released a draft guide to offer their perspective and thoughts on the development of treatments for stimulant use disorder.

What is the risk of diabetes, hypertension, or hyperlipidemia with antipsychotic polypharmacy in patients with schizophrenia? Researchers investigated these associations in a population-based prospective cohort study.

ADHD in adults lead to educational, occupational, relational, and judgment impairments.

Psychiatry will be needed to help heal the mental wounds in the Mideast.

A psychiatrist reflects on blue fortitude as he visits the Columbine Memorial.

Elizabeth Lowenhaupt, MD, CCHP, shares her insights and experiences on correctional psychiatry and juvenile mental health as she looks toward the future of the field.

From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

Does psychiatry’s future lean towards online practice?

Searching for those rare rainbows…

“Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray.”

The investigators also concluded that depression screening alone may not be sufficient to effectively identify suicide risk.

Does telepsychiatry lessen the therapeutic alliance?

Experiences of awe—have you had one?

Look through the eyes of a medical health care team in a refugee camp with a focus on children’s mental health.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

Avoiding hubris: connections between the unsinkable ship and psychiatry.

Is psilocybin a viable treatment for MDD? Researchers performed a phase 2, double blind trial of single-dose psilocybin in patients with treatment resistant depression.

What application do Gandhi’s teachings have in psychiatry?

The experts weighed in on a wide variety of psychiatric issues for the September 2023 issue of Psychiatric Times.

From connections between cannabis use and schizophrenia to some non-psychiatric medications that may worsen symptoms of major depression, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of September.

What is new in research on sleep?

Do you have any recent experiences of awe?

Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.

The treatment, if approved, “will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”

Awe and psychiatry: what is the connection for you?

Concussion is the most common type of traumatic brain injury. Unfortunately, many individuals that sustain a concussion are not seen in a medical setting. All health care providers should receive training in identifying the signs and symptoms of concussion in order to provide proper guidance and referral for specialized treatment.

The ongoing clinical trial is also studying the drug’s efficacy in the treatment of MDD.